Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 953 matching trials from the live ClinicalTrials.gov search.
Filters: Charlotte, North Carolina Clear all
Completed Phase 3 Interventional Results available

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

NCT00409188
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
1,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
49
States / cities
Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

NCT00006412
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Pravastatin sodium, Fenofibrate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
57
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02813265
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
918 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 21, 2026, 9:45 AM EDT
Not listed Phase 3 Interventional Results available

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

NCT01949337
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
enzalutamide, abiraterone, prednisone
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
527
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 382 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

NCT01471574
View directory record Official record
Conditions
Hepatitis C, Genotype 1
Interventions
Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 2 Interventional Results available

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

NCT01467505
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

NCT00006462
View directory record Official record
Conditions
Leukemia
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
197
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

NCT02315469
View directory record Official record
Conditions
Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Comprehensive Geriatric Assessment, Questionnaire Administration
Other
Lead sponsor
NRG Oncology
Other
Eligibility
70 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
392
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 282 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

NCT00959894
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (Intelence), Truvada
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

NCT03288545
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
Interventions
enfortumab vedotin (EV), pembrolizumab, cisplatin, carboplatin, gemcitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
83
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Not applicable Interventional Results available

The Merit WRAPSODY AV Access Efficacy Study (WAVE)

NCT04540302
View directory record Official record
Conditions
Venous Stenosis, Venous Occlusion
Interventions
Merit WRAPSODY Endovascular Stent Graft, PTA
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
33
States / cities
Tempe, Arizona • Tucson, Arizona • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Active, not recruiting Not applicable Interventional

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
24
States / cities
Stanford, California • Darien, Connecticut • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

NCT05832151
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
CIN-102 Dose 15mg or 10mg, Placebo
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
100
States / cities
Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 21, 2026, 9:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Auditory Biofeedback Gait Training Individuals With Chronic Ankle Instability

NCT06868316
View directory record Official record
Conditions
Ankle Sprains, Ankle Injuries and Disorders
Interventions
Walking, Rucking, Running
Other
Lead sponsor
Danielle Torp
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Lexington, Kentucky • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Recruiting Phase 3 Interventional

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

NCT07089888
View directory record Official record
Conditions
Tophaceous Gout
Interventions
Allopurinol, Dotinurad
Drug
Lead sponsor
Crystalys Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
95
States / cities
Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional

Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

NCT01323348
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy
Interventions
Diabetes Education
Behavioral
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Loma Linda, California • Santa Barbara, California • Fort Lauderdale, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732
View directory record Official record
Conditions
HIV-1 Infection
Interventions
B/F/TAF, NRTIs, Third Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 21, 2026, 9:45 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

NCT07723248
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

NCT01354431
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
34
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

NCT03918629
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
1,994 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
52
States / cities
Athens, Alabama • Huntsville, Alabama • Chandler, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 21, 2026, 9:45 AM EDT
Recruiting Phase 3 Interventional

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

NCT07061977
View directory record Official record
Conditions
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions
Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
341
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 263 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

NCT00001045
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
57
States / cities
Los Angeles, California • San Francisco, California • San Jose, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00110019
View directory record Official record
Conditions
Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Placebo, Sorafenib Tosylate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
218
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 21, 2026, 9:45 AM EDT